Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Whanin Pharmaceutical Company
Double blinded, Randomized, Placebo Controlled, Multi-center, Phase 2 : Exploratory Clinical Study to Evaluate the Efficacy, Dose-response and Safety of WIN-901X in Asthma Patients
Age
20–79
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Greater than or equal to 20 and less than 80 years of age
Have physician diagnosed asthma with irreversible airway obstruction at least 6 months prior to the screening
FEV1 between 60% and 85% before inhaling fast-acting bronchodilator at screening
No history of smoking at least one year prior to the screening
Having voluntarily signed an informed consent
You may not be if
Have visited emergency room due to the worsening asthma symptoms, within 4 weeks before the screening
Have been hospitalized due to an acute worsening of asthma within 3 months before the screening
Have a history of laryngitis, pyrexia, sinusitis, otitis media, respiratory tract infection, and infectious rhinitis within 4 weeks prior to the screening
Have malignant tumor
Clareo Health | Safety and Efficacy of WIN-901X in Asthma
